Abstract 1014TiP
Background
Currently, 70%-80% of liver cancer patients have recurrence within 5 years after radical surgery. Therefore, determining effective treatment methods for liver cancer is still a major issue of global concern. Recombinant human adenovirus type 5 (rAd5, H101) is the world's first approved oncolytic virus product in China, rAd5 and transarterial chemoembolization (TACE) has significant anti-tumor effect in treatment of liver cancer. Compared with TACE, transhepatic arterial embolization (TAE) sequential thermal ablation may significantly improve the overall survival (OS) rate of liver cancer patients. This study aims to explore the efficacy and safety of rAd5 combined with TAE sequential thermal ablation in treatment of liver cancer, and to further explore the local and systemic immunological changes in patients.
Trial design
This is a prospective, open-label, randomized, parallel controlled study, 110 patients with medium- and high-risk recurrent liver cancer are expected to enroll. Key inclusion criteria are: age ≥18 and ≤70; ECOG performance status of 0-1; Child-Pugh score ≤7; and the expected survival time ≥3 months. All participants are randomized 1:1 to receive rAd5 combined with TAE and thermal ablation (experimental group) or TAE and thermal ablation (control group). Before, 10 mg dexamethasone was intravenously administered. rAd5 (H101) will be intratumorally injected into the hepatic segmental artery, the dosage is adjusted according to the maximum diameter of lesions: ≤10 cm, 1.0×1012 vp/day; ≥10 cm, 1.5×1012 vp/ day, 28 days for a cycle (4 cycles totally). 1-3 weeks after rAd5 injection and TAE or TAE, thermal ablation treatment will be performed if patients have residual tumor. Patients will be followed up at 1, 3, 6 and 12 months after treatment. The primary endpoint is objective response rate. Secondary endpoints include progression free survival, disease control rate, one-year OS and quality of life score. Exploratory endpoints are the changes from baseline in CD4+, CD8+, Treg, Th1 and Th2. The adverse events will be monitored.
Clinical trial identification
ChiCTR2300067319 (http://www.chictr.org.cn/); Release date, January 04, 2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18